NCT02838238Unknown2 期
A Randomized, Phase II Study Comparing Single X (Xeloda/Capetabine) With Placebo as Postoperative Adjuvant Treatment for Elder Breast Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 入组人数
- 300
- 试验地点
- 1
- 主要终点
- Disease-free survival
研究概览
简要总结
Our study is a prospective, randomized phase II clinical trial, to compare the efficacy and safety profiles of single X versus placebo as adjuvant chemotherapy regimens for elder breast cancer patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 70 Years 至 —（Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Inclusion Criteria:
- •Age >= 70 years old.
- •Performance status (Karnofsky index) >=
- •Histological diagnosis of invasive breast cancer (T3-T4,N0-1,M0). Tumor must bu hormone receptor negative. Time window between surgery and study randomization must be less than 60 days.
- •Positive axillary lymph nodes defined as at least 1 out of 10 nodes with presence of disease. If sentinel node technique is used, sentinel node can be the only node affected.
- •Status of hormone receptors, HER2 status, Ki-67 index and p53 in primary tumour. ER and PR negative. And patients with positive HER-2 status should revceive the standard anti-targeted therapy.
- •Written informed consent. Patients are able to comply with treatment and study follow-up.
- •Patients must not present evidence of metastatic disease.
- •Normal electrocardiogram (EKG) in the 12 weeks prior to randomization. If needed, normal cardiac function must be confirmed by left ventricular ejection fraction (LVEF).
- •Laboratory results (within 14 days prior to randomization):
- •Hematology: neutrophils >= 2.0x10^9/l; platelets >= 100x10^9/l; hemoglobin >= 10 mg/dl; Hepatic function: total bilirubin <= 1 upper normal limit (UNL); SGOT and SGPT <= 2.5 UNL; alkaline phosphatase <= 2.5 UNL. If values of SGOT and SGPT > 1.5 UNL are associated to alkaline phosphatase > 2.5 UNL, patient is not eligible; Renal function: creatinine <= 175 mmol/l (2 mg/dl); creatinine clearance >= 60 ml/min.
- •·Complete stage workup during the 12 weeks prior to randomization (mammograms are allowed within a 20 week window). All patients must have a bilateral mammogram, thorax x-ray, abdominal echography and/or computed tomography (CT)-scan. If bone pain, and/or alkaline phosphatase elevation, a bone scintigraphy is mandatory. This test is recommended for all patients. Other tests: as clinically indicated.
排除标准
- •Prior systemic therapy for breast cancer.Or prior therapy with capecitabine for any malignancy.
- •Prior radiotherapy for breast cancer.
- •Bilateral invasive breast cancer.
- •Any T4 or N2-3 or M1 tumour.
- •Pre-existing grade >= 2 motor or sensorial neurotoxicity (National Cancer Institute Common Toxicity Criteria version 2.0 [NCI CTC v-2.0]).
- •Any other serious medical pathology, such as congestive heart failure; unstable angina; history of myocardial infarction during the previous year; uncontrolled HA or high risk arrhythmias.
- •History of neurological or psychiatric disorders, which could preclude the patients from free informed consent.
- •Active uncontrolled infection.
- •Active peptic ulcer; unstable diabetes mellitus.
- •Previous or current history of neoplasms different from breast cancer, except for skin carcinoma, cervical in situ carcinoma, or any other tumour curatively treated and without recurrence in the last 10 years; ductal in situ carcinoma in the same breast; lobular in situ carcinoma.
- •Chronic treatment with corticosteroids.
- •Concomitant treatment with raloxifene, tamoxifen or other selective estrogen receptor modulators (SERMs), either for osteoporosis treatment or for prevention. These treatments must stop before randomisation.
- •Concomitant treatment with other investigational products; participation in other clinical trials with a non-marketed drug in the 20 previous days before randomization.
- •Concomitant treatment with another therapy for cancer.
研究组 & 干预措施
X
Experimental
Capecitabine 1250mg/m², bid, po, d1-14, every 3 weeks for 6 cycles
干预措施: Capecitabine (Drug)
Placebo
Placebo Comparator
Placebo, bid, po, d1-14, every 3 weeks for 6 cycles
干预措施: Placebo (Drug)
结局指标
主要结局
Disease-free survival
时间窗: 5 years
Adverse event rate (CTCAE v. 3.0)
时间窗: 5 years
次要结局
- Overall survival(5 years)
研究者
Qiang SUN
Chief of Dept. Breast Surgery, Professor
Peking Union Medical College Hospital
研究点 (1)
Loading locations...
相似试验
Unknown
2 期
Standard Chemotherapy Followed by Capecitabine as Prolonged Postoperative Adjuvant Treatment for Breast CancerBreast CancerNCT02842099Peking Union Medical College Hospital500
Unknown
2 期
A Study of TC(Docetaxel and Carboplatin) Regimen With or Without Nimotuzumab in Recurrent Metastatic Oral Squamous Cell CarcinomaOral Squamous Cell CarcinomaNCT04367909Xin-Hua Xu68
Unknown
2 期
A Study of Sintilimab or Placebo in Combination With Chemotherapy as Second-line Treatment for Patients With Stage IV Nonsquamous Non-small Cell Lung Cancer With Wild-type EGFR After Failure With Platinum-Containing Chemotherapy.Nonsquamous Non-Small Cell Lung CancerNCT03863483Xin-Hua Xu70
Unknown
2 期
A Study of Sintilimab Compared With Docetaxel or Pemetrexed as Second-line Treatment for Patients With Stage IV Nonsquamous Non-small Cell Lung Cancer After Failure With Platinum-Containing ChemotherapyNonsquamous Non-Small Cell Lung CancerNCT03830411Xin-Hua Xu76
Unknown
2 期
Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced Squamous NSCLC With Brain MetastasesNon-Small Cell Squamous Lung CancerBrain MetastasesNCT05207904Sun Yat-sen University41